Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 410

1.

Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia.

Janssens B, Raleigh B, Soeung S, Akao K, Te V, Gupta J, Vun MC, Ford N, Nouhin J, Nerrienet E.

Pediatrics. 2007 Nov;120(5):e1134-40. Epub 2007 Oct 22.

PMID:
17954553
2.

Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya.

Song R, Jelagat J, Dzombo D, Mwalimu M, Mandaliya K, Shikely K, Essajee S.

Pediatrics. 2007 Oct;120(4):e856-61. Epub 2007 Sep 10.

PMID:
17846147
3.

Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.

Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W.

Clin Infect Dis. 2007 Feb 1;44(3):447-52. Epub 2006 Dec 27.

PMID:
17205457
4.

Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive antiretroviral regimen.

Gandhi T, Nagappan V, Cinti S, Wei W, Kazanjian P.

Clin Infect Dis. 2007 Oct 15;45(8):1085-92. Epub 2007 Sep 14.

PMID:
17879930
5.
6.

Immunologic function and virologic suppression among children with perinatally acquired HIV Infection on highly active antiretroviral therapy.

Rutstein RM, Gebo KA, Flynn PM, Fleishman JA, Sharp VL, Siberry GK, Spector SA.

Med Care. 2005 Sep;43(9 Suppl):III15-22.

PMID:
16116305
7.

Efficacy of first-line, WHO recommended generic HAART regimens in Indian children.

Parakh A, Dubey AP, Kumar A, Maheshwari A, Saxena R.

Kathmandu Univ Med J (KUMJ). 2009 Jul-Sep;7(27):220-5.

PMID:
20071866
8.

Response to changes in antiretroviral therapy after genotyping in human immunodeficiency virus-infected children.

Cohen NJ, Oram R, Elsen C, Englund JA.

Pediatr Infect Dis J. 2002 Jul;21(7):647-53.

PMID:
12237597
9.

Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.

Jaspan HB, Berrisford AE, Boulle AM.

Pediatr Infect Dis J. 2008 Nov;27(11):993-8. doi: 10.1097/INF.0b013e31817acf7b.

PMID:
18818556
10.

Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy.

Kamya MR, Mayanja-Kizza H, Kambugu A, Bakeera-Kitaka S, Semitala F, Mwebaze-Songa P, Castelnuovo B, Schaefer P, Spacek LA, Gasasira AF, Katabira E, Colebunders R, Quinn TC, Ronald A, Thomas DL, Kekitiinwa A; Academic Alliance for AIDS Care and Prevention in Africa.

J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):187-93.

PMID:
17693883
11.

Paediatric antiretroviral therapy audit in South London.

Doerholt K, Sharland M, Ball C, DuMont G.

HIV Med. 2002 Jan;3(1):44-8.

12.

Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.

Pujades-Rodríguez M, O'Brien D, Humblet P, Calmy A.

AIDS. 2008 Jul 11;22(11):1305-12. doi: 10.1097/QAD.0b013e3282fa75b9.

PMID:
18580610
13.

Short communication: three years follow-up of first-line antiretroviral therapy in cambodia: negative impact of prior antiretroviral treatment.

Ségéral O, Limsreng S, Nouhin J, Hak C, Ngin S, De Lavaissière M, Goujard C, Taburet AM, Nerrienet E, Delfraissy JF, Ouk V, Dulioust A.

AIDS Res Hum Retroviruses. 2011 Jun;27(6):597-603. doi: 10.1089/AID.2010.0125. Epub 2011 Jan 17.

PMID:
21083413
14.

[Effectiveness of antiretroviral therapy in HIV-1 infected children. A cross-sectional study].

González Tomé MI, Ramos Amador JT, Sánchez Granados JM, Guillén S, Rojo P, Ruiz Contreras J.

An Pediatr (Barc). 2005 Jan;62(1):32-7. Spanish.

15.

Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.

Resino S, Larrú B, Maria Bellón J, Resino R, de José MI, Navarro M, Léon JA, Ramos JT, Mellado MJ, Muñoz-Fernández MA.

BMC Infect Dis. 2006 Jul 11;6:107.

16.

Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.

Reddi A, Leeper SC, Grobler AC, Geddes R, France KH, Dorse GL, Vlok WJ, Mntambo M, Thomas M, Nixon K, Holst HL, Karim QA, Rollins NC, Coovadia HM, Giddy J.

BMC Pediatr. 2007 Mar 17;7:13.

17.

Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort.

Scherpbier HJ, Bekker V, van Leth F, Jurriaans S, Lange JM, Kuijpers TW.

Pediatrics. 2006 Mar;117(3):e528-36. Epub 2006 Feb 15.

PMID:
16481448
18.

Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure.

Uy J, Armon C, Buchacz K, Wood K, Brooks JT; HOPS Investigators.

J Acquir Immune Defic Syndr. 2009 Aug 1;51(4):450-3. doi: 10.1097/QAI.0b013e3181acb630.

PMID:
19474757
19.

An algorithm to optimize viral load testing in HIV-positive patients with suspected first-line antiretroviral therapy failure in Cambodia.

Lynen L, An S, Koole O, Thai S, Ros S, De Munter P, Sculier D, Arnould L, Fransen K, Menten J, Boelaert M, Van den Ende J, Colebunders R.

J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):40-8. doi: 10.1097/QAI.0b013e3181af6705.

PMID:
19550349
20.

Chinese pediatric highly active antiretroviral therapy observational cohort: a 1-year analysis of clinical, immunologic, and virologic outcomes.

Zhang F, Haberer JE, Zhao Y, Dou Z, Zhao H, He Y, Cao GH.

J Acquir Immune Defic Syndr. 2007 Dec 15;46(5):594-8.

PMID:
18043313

Supplemental Content

Support Center